Innate Pharma S.A. ADS
IPHA Real Time Price USDRecent trades of IPHA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in IPHA holdings by institutional investors
Quarterly net insider trading by IPHA's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
IPHA Estimated quarterly lobbying spending
IPHA Revenue by Segment or Geography
New IPHA patent grants
-
Patent Title: Treatment of t cell lymphoma Oct. 21, 2025
-
Patent Title: Nkp46 binding agents Jul. 22, 2025
-
Patent Title: Multispecific nk engager protein Mar. 18, 2025
-
Patent Title: Humanized antibodies with increased stability Feb. 18, 2025
-
Patent Title: Nucleic acids encoding and methods of producing proteins comprising antibody chains Jan. 21, 2025
-
Patent Title: Compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma Sep. 10, 2024
-
Patent Title: Treatment regimens using anti-nkg2a antibodies Jul. 16, 2024
-
Patent Title: Treatment of peripheral t cell lymphoma Jun. 04, 2024
-
Patent Title: Treatment with anti-kir3dl2 agents Apr. 30, 2024
-
Patent Title: Cd73 blockade Apr. 16, 2024
-
Patent Title: Variable regions for nkp46 binding proteins Feb. 06, 2024
-
Patent Title: Kir3dl2 binding agents Jan. 02, 2024
-
Patent Title: Nkp46 binding proteins Dec. 19, 2023
-
Patent Title: Treatment of head and neck cancer Oct. 24, 2023
-
Patent Title: Siglec-9-neutralizing antibodies Apr. 11, 2023
-
Patent Title: Compositions and methods for treating cancer Feb. 14, 2023
-
Patent Title: Neutralization of inhibitory pathways in lymphocytes Feb. 07, 2023
-
Patent Title: Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer Sep. 20, 2022
-
Patent Title: Antibodies that bind human cd39 and inhibit atpase activity of a soluble extracellular domain human cd39 polypeptide Jul. 05, 2022
-
Patent Title: Nkp46 binding agents Jul. 05, 2022
-
Patent Title: Compositions and methods for regulating nk cell activity Jun. 21, 2022
-
Patent Title: Multispecific nk engager protein Mar. 08, 2022
-
Patent Title: Treatment of cancers using anti-nkg2a agents Jan. 18, 2022
-
Patent Title: Multispecific antigen binding proteins Dec. 28, 2021
-
Patent Title: Cd73 blocking agents Sep. 28, 2021
-
Patent Title: Siglec-10 antibodies Aug. 10, 2021
-
Patent Title: Compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma Aug. 03, 2021
-
Patent Title: Siglec neutralizing antibodies Aug. 03, 2021
-
Patent Title: Humanized antibodies with increased stability Jul. 20, 2021
-
Patent Title: Variable regions for nkp46 binding proteins May. 11, 2021
-
Patent Title: Neutralization of inhibitory pathways in lymphocytes Dec. 22, 2020
-
Patent Title: Cd73 blockade Sep. 08, 2020
-
Patent Title: Methods for detecting tissue infiltrating nk cells Aug. 11, 2020
-
Patent Title: Neutralization of inhibitory pathways in lymphocytes Jul. 14, 2020
-
Patent Title: Treatment regimens using anti-nkg2a antibodies Jun. 09, 2020
-
Patent Title: Enzymatic conjugation of antibodies Jun. 09, 2020
-
Patent Title: Kir3dl2 binding agents Mar. 03, 2020
-
Patent Title: Tlr3 binding agents Apr. 17, 2018
-
Patent Title: Methods for treatment of recurrent hematological malignancies Dec. 19, 2017
-
Patent Title: Anti-kir3d antibodies Nov. 28, 2017
-
Patent Title: Enzymatic conjugation of antibodies Sep. 19, 2017
-
Patent Title: Enzymatic conjugation of polypeptides Aug. 01, 2017
-
Patent Title: Enzymatic conjugation of polypeptides Aug. 30, 2016
-
Patent Title: Tlr3 binding agents Jul. 12, 2016
-
Patent Title: Anti-kir3d antibodies Nov. 10, 2015
-
Patent Title: Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders Jun. 30, 2015
-
Patent Title: Polymorphic form of chdmapp, method of preparation thereof, and pharmaceutical composition comprising same May. 27, 2014
-
Patent Title: Methods of treating patients having tlr3-positive cancer May. 06, 2014
-
Patent Title: Compositions and methods for detecting tlr3 Sep. 25, 2012
-
Patent Title: Class of γδ t cells activators and use thereof Aug. 03, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to IPHA from public contracts
Recent insights relating to IPHA
Recent picks made for IPHA stock on CNBC
ETFs with the largest estimated holdings in IPHA
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $IPHA stock a Buy, Sell, or Hold?
- What is the price target for $IPHA stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $IPHA stock?
- Who owns the most shares of $IPHA stock?
- What funds own $IPHA stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IPHA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.